

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5990399

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOBLAST PHARMA, LTD.	02/15/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SEELOS THERAPEUTICS, INC.
<b>Street Address:</b>	300 PARK AVENUE, 12TH FLOOR
<b>City:</b>	NEW YORK
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10022
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16263707
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	+1 (650) 839-5080
<b>Email:</b>	apsi@fr.com
<b>Correspondent Name:</b>	CALEB A. BATES
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	47542-0018006
<b>NAME OF SUBMITTER:</b>	JILL A. WRIGHT
<b>SIGNATURE:</b>	/Jill A. Wright/
<b>DATE SIGNED:</b>	03/02/2020
<b>Total Attachments: 4</b>	
source=Seelos - Bioblast - Assignment of Patents (2-15-19)(97539632_1) (003)_Redacted#page1.tif	
source=Seelos - Bioblast - Assignment of Patents (2-15-19)(97539632_1) (003)_Redacted#page2.tif	
source=Seelos - Bioblast - Assignment of Patents (2-15-19)(97539632_1) (003)_Redacted#page3.tif	
source=Seelos - Bioblast - Assignment of Patents (2-15-19)(97539632_1) (003)_Redacted#page4.tif	

## ASSIGNMENT OF PATENTS

**WHEREAS, BIOBLAST PHARMA, LTD.**, an Israeli corporation ("**Seller**"), owns all right, title and interest in and to certain new and useful improvements for which it owns the patents and applications for patents listed on **SCHEDULE A** attached hereto, including the inventions described therein and the patents issued and reissued thereon (collectively, the "**Patents**"), the renewals therefor and all claims for past infringement thereof; and

**WHEREAS, SEELOS THERAPEUTICS, INC.**, a Nevada corporation ("**Buyer**"), is desirous of acquiring the entire right, title, and interest in and to the Patents, the renewals therefor and all claims for past infringement thereof.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:

1. **Assignments.** Seller does hereby sell, assign, transfer, convey and deliver unto Buyer, its successors and assigns, its entire right, title and interest throughout the world in and to the Patents and divisions, continuations and continuations-in-part thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent which may hereafter be filed for said improvements in any country or countries foreign to the United States, and all Letters Patent which may be granted for said improvements in any country or countries foreign to the United States and all extensions, renewals and reissues thereof, together with all rights of registration, maintenance, and protection thereof in any form, and all rights of recovery and of legal action for past infringements and of interference proceedings and reexamination involving such patents.

■ [REDACTED]

■ [REDACTED]

■ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Signature Page Follows]

[REDACTED]

**IN WITNESS WHEREOF**, the undersigned has duly executed this Assignment of Patents as of this 15th day of February, 2019.

**BIOBLAST PHARMA, LTD.**

By: *D. Megiddo*

Name: Dr. Dalia Megiddo

Title: Interim Chief Executive Officer

**[REDACTED]**

## **SCHEDULE A**

### **PATENTS**

1. IV trehalose for protein aggregation in myopathic and neurodegenerative diseases (W0 2014181333- PCT- pending)
2. IV trehalose for OPMD (9084720 – US granted)
3. IV trehalose for SCA (9125924 –US granted)
4. IV trehalose for Huntington's disease (9572825 – US granted)
5. IV trehalose formulation US –US20170020905A1 pending